waning immunity – Page 7 – Communicable Diseases Research

Oral antivirals for the prevention and treatment of SARS-CoV-2 infection

SARS-CoV-2 감염 예방 및 치료를 위한 경구용 항바이러스제

Article

Published on 2022-03-012022-09-11
Journal: AIDS reviews [Category] SARS, 변종, 치료제,

[키워드] advent Antiviral antiviral therapy antivirals benefit classical combination therapies combination therapy complications COVID-19 COVID-19 disease COVID-19 pandemic Disease progression dissemination Each early treatment Emergency use authorization escape mutant Formulation Infection landscape life-threatening Long-ActingAntivirals manifestation medications Medicine molnupiravir monoclonal antibodies monoclonal antibody Mutagenesis Nirmatrelvir offer oral Oral Remdesivir parenteral administration polymerase Prevent Prophylaxis protease protease inhibitors PROTECT provided reduce regulatory agencies regulatory agency Remdesivir required SARS-CoV-2 SARS-COV-2 infection severe COVID-19 disease small molecule treat Treatment Vaccine variant viral illnesses waning immunity
[DOI] 10.24875/AIDSRev.22000001 PMC 바로가기 [Article Type] Article

Trends in COVID-19 Vaccine Administration and Effectiveness Through October 2021

2021년 10월까지의 COVID-19 백신 투여 및 효과 동향

Article

Published on 2022-03-012022-09-11
Journal: JAMA Network Open [Category] SARS, 변종,

[키워드] 95% CI Ad26 African American Alaska Asian black BNT162b2 Chain Reaction cohort study COVID-19 COVID-19 vaccine COVID-19 vaccines defined delta variant effective Effectiveness EHR Electronic health record evaluate Health health record health system health systems Hispanic Hospital admission Hospitalization hospitalizations individual Infection limit lowest mRNA mRNA-1273 mRNA-1273 vaccine multiracial Native outcome participant PCR PCR test polymerase chain polymerase chain reaction positive positive SARS-CoV-2 PCR positive SARS-CoV-2 PCR test Prevalence rate ratio receipt rurality SARS-CoV-2 second dose single dose trend unique vaccination vaccination rate vaccination rates Vaccine vaccine administration Vaccines waning immunity were assessed were used white
[DOI] 10.1001/jamanetworkopen.2022.5018 PMC 바로가기 [Article Type] Article

Diphtheria-tetanus-pertussis vaccine: past, current & future

Article

Published on 2022-02-282024-09-02
Journal: Future Microbiol [Category] 백일해, 파상풍,

[키워드] Acellular pertussis vaccine animal and human trials Diphtheria DTP vaccine experimental vaccine pertussis prevention Tetanus waning immunity whole-cell pertussis vaccine
PMC 바로가기

Influence of heterogeneous age-group contact patterns on critical vaccination rates for herd immunity to SARS-CoV-2

Article

Published on 2022-02-162022-10-29
Journal: Scientific Reports [Category] COVID-19, COVID19(2023년), MERS, SARS,

Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination

Article

Published on 2022-02-132022-10-28
Journal: Vaccines [Category] COVID-19,

Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs

Viewpoint

Published on 2022-02-072022-10-28
Journal: Vaccines [Category] COVID-19,

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

SARS-CoV-2 및 우려 변종에 대한 특성, 효능 및 효과에 대한 COVID-19 백신 비교: 서술적 검토

Review

Published on 2022-02-012022-09-11
Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 변종,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adverse effects adverse event adverse events agency Alpha Analysis anaphylaxis AZD1222 benefit Beta bioRxiv BNT162b2 booster dose Characteristics Comparative analysis CoronaVac coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines Critical death Delta Delta variants dose doses effective Effectiveness Efficacy Evidence Gamma Google Scholar Heterologous highest Hospitalization Immunity immunization Infection mass vaccination medRxiv mRNA mRNA vaccine mRNA vaccines mRNA-1273 myocarditis pandemic Phase III trials Prevent reduced reference Regulatory review Safe SARS-CoV-2 SARS-COV-2 infection seroneutralization severe acute respiratory syndrome Coronavirus severe COVID-19 Severe infection severe infections symptomatic symptomatic case symptomatic cases symptomatic COVID-19 the vaccine vaccination Vaccine Vaccines variant variants variants of concern waning immunity website
[DOI] 10.1016/j.cmi.2021.10.005 PMC 바로가기 [Article Type] Review

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article

암 환자를 위한 항 SARS-CoV-2 백신 3차 접종: 체액 반응을 모니터링해야 합니까? 입장 기사

Review

Published on 2022-02-012022-09-12
Journal: European journal of cancer (Oxford, England : 1990 [Category] COVID19(2023년), MERS, SARS, 진단,

Kinetics and persistence of cellular and humoral immune responses to SARS‐CoV‐2 vaccine in healthcare workers with or without prior COVID‐19

이전 COVID-19 유무에 관계없이 의료 종사자의 SARS-CoV-2 백신에 대한 세포 및 체액 면역 반응의 동역학 및 지속성

Original Article

Published on 2022-01-182022-09-10
Journal: Journal of Cellular and Molecular Medicine [Category] MERS, 변종, 진단,

[키워드] antibody antibody levels baseline BNT162b2 BNT162b2 mRNA vaccine cellular cellular immune responses circulating viral variant conducted COVID‐19 death declining decrease descending diagnosed dose form healthcare worker Healthcare workers highest Hospitalization humoral immune response humoral responses IFN IFN‐γ IgA level IgA levels IgG antibodies immune response immune response post‐infection immune response post‐vaccination immune responses Infection Kinetics longitudinal study mRNA vaccine natural infection neutralization Neutralization assay Neutralizing activity Neutralizing antibodies new infections of BNT162b2 participant persistence preserved SARS‐CoV‐2 SARS‐CoV‐2 infection SARS‐CoV‐2 infection secretion significantly spike‐specific CD4⁺ T cell spike‐specific CD8⁺ T cell subject T‐cell the disease titre Vaccine vaccine dose Viral waning immunity
[DOI] 10.1111/jcmm.17186 PMC 바로가기 [Article Type] Original Article

Covid-19 Vaccine Effectiveness in New York State

뉴욕주의 Covid-19 백신 효과

Comparative Study

Published on 2022-01-132022-09-11
Journal: The New England Journal of Medicine [Category] Fulltext, SARS, 변종,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Admission age B.1.617.2 BNT162b2 cause circulating variants Cohort cohorts coronavirus coronavirus disease Coronavirus disease 2019 Decline declined declines defined delta variant diagnosed drug Drug administration Effectiveness food Food and Drug Administration greater hospital Hospitalization laboratory-confirmed Laboratory-confirmed COVID-19 median mRNA mRNA-1273 nadir New York Older predominant Prevalence recipient remained SARS-CoV-2 severe acute respiratory syndrome Coronavirus state the median the United State United States used data vaccination Vaccine Vaccines variant waning immunity
[DOI] 10.1056/NEJMoa2116063 PMC 바로가기 [Article Type] Comparative Study